Atrial Fibrillation News and Research

RSS
Atrial fibrillation (AF) is the most common arrhythmia. An arrhythmia is a problem with the speed or rhythm of the heartbeat. A disorder in the heart’s electrical system causes AF and other types of arrhythmia. AF occurs when rapid, disorganized electrical signals in the heart’s two upper chambers, called the atria, cause them to contract very fast and irregularly (this is called fibrillation). As a result, blood pools in the atria and isn’t pumped completely into the heart’s two lower chambers, called the ventricles. When this happens, the heart’s upper and lower chambers don’t work together as they should. Often, people who have AF may not even feel symptoms. However, even when not noticed, AF can lead to an increased risk of stroke. In many patients, particularly when the rhythm is extremely rapid, AF can cause chest pain, heart attack, or heart failure. AF may occur rarely or every now and then, or it may become a persistent or permanent heart rhythm lasting for years.
AliveCor Mobile ECG to be integrated into LifeWatch's remote cardiac monitoring service

AliveCor Mobile ECG to be integrated into LifeWatch's remote cardiac monitoring service

Cardiome files NDS with Health Canada's TPD for approval of intravenous vernakalant

Cardiome files NDS with Health Canada's TPD for approval of intravenous vernakalant

Patients treated at emergency departments for hypertension on the rise in US

Patients treated at emergency departments for hypertension on the rise in US

American College of Cardiology launches new STS/ACC TAVR In-Hospital Mortality Risk App

American College of Cardiology launches new STS/ACC TAVR In-Hospital Mortality Risk App

Right atrial function could be prognostic in PAH

Right atrial function could be prognostic in PAH

ER stroke cases have some degree of preventability, UCI study shows

ER stroke cases have some degree of preventability, UCI study shows

Older men with sleep-disordered breathing at greater risk of developing atrial fibrillation

Older men with sleep-disordered breathing at greater risk of developing atrial fibrillation

XARELTO reduces rates of major bleeding, recurrent blood clots in people with deep vein thrombosis

XARELTO reduces rates of major bleeding, recurrent blood clots in people with deep vein thrombosis

Potential for chemotherapy-free standard of care in advanced mantle cell lymphoma

Potential for chemotherapy-free standard of care in advanced mantle cell lymphoma

Advances in leadless pacing: an interview with Dr. Reddy

Advances in leadless pacing: an interview with Dr. Reddy

STSI launches home-based clinical trial that uses wearable sensors to identify people with AFib

STSI launches home-based clinical trial that uses wearable sensors to identify people with AFib

Study shows sleep-disordered breathing predicts AF development in older men

Study shows sleep-disordered breathing predicts AF development in older men

AF Association survey shows impact of AF diagnosis on patients

AF Association survey shows impact of AF diagnosis on patients

White coat hypertension, masked hypertension increase cardiovascular events over the years

White coat hypertension, masked hypertension increase cardiovascular events over the years

Screening for asymptomatic atrial fibrillation could reduce risk of stroke, premature death

Screening for asymptomatic atrial fibrillation could reduce risk of stroke, premature death

The American Heart Association and Heart Rhythm Society Unite to Improve Cardiovascular Research, Care

The American Heart Association and Heart Rhythm Society Unite to Improve Cardiovascular Research, Care

Pacemakers can detect AF and enable initiation of anticoagulation for stroke prevention

Pacemakers can detect AF and enable initiation of anticoagulation for stroke prevention

FDA grants accelerated approval to Praxbind (idarucizumab)

FDA grants accelerated approval to Praxbind (idarucizumab)

Primary care physicians often under- or over-estimate stroke and bleeding risk in AF patients

Primary care physicians often under- or over-estimate stroke and bleeding risk in AF patients

Boehringer Ingelheim announces FDA approval of Praxbind (idarucizumab)

Boehringer Ingelheim announces FDA approval of Praxbind (idarucizumab)

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.